Abstract 40P
Background
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality globally. Sorafenib remains the globally accepted systemic first-line treatment for advanced HCC patients. Due to the heterogeneity of HCC, patients usually develop drug resistance within six months. The underlying mechanisms of sorafenib resistance in HCC remain to be fully elucidated.
Methods
We established sorafenib-resistant HCC cell lines and characterized them using functional and microarray-based approaches. The subcellular localization of target proteins was determined by western blot analysis. Additionally, we generated an inducible system of constitutively active YAP1 mutant (YAP1-8SA) in Huh7. Furthermore, we utilized immunocompetent murine HCC model to evaluate the efficacy of galunisertib, sorafenib or their combination treatment.
Results
Sorafenib-resistant HCC cells exhibited higher IC50 values for sorafenib. Both Huh7 parental (Huh7-P) and sorafenib-resistant cells (Huh7-sorR) were selected for further analysis. Huh7-sorR demonstrated characteristics of EMT and de-differentiation, and both YAP1 and TGFβ1 signaling pathway were activated. Upon TGFβ1 stimulation in Huh7-P, the activation of YAP1 signaling pathway was observed. Similarly, constitutive YAP1 activation in Huh7-YAP8SA increased the protein level of TGFβ1. These results suggesting a positive feedback loop between YAP1 and TGFβ signaling pathways. The treatment of galunisertib suppressed the YAP1 signaling pathway in Huh7-sorR. Furthermore, the combination treatment of galunisertib and sorafenib greatly suppressed the growth of Huh7-sorR cells. In the in vivo study, the combination treatment of galunisertib and sorafenib also demonstrated prolonged overall survival.
Conclusions
We have identified YAP1-TGFβ1 axis as the underlying mechanism driving the sorafenib resistance in HCC. Our results showed that galunisertib could sensitize the resistant cells to sorafenib, by blocking the canonical TGFβ signaling pathway and its positive feedback to YAP pathway. TGFβ1 has been shown to be a potential biomarker for drug resistance and combination of sorafenib and galunisertib treatment would be an effective treatment regime for HCC recurrence patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
National Cancer Centre Singapore.
Funding
National Medical Research Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract